JAK Inhibitor News and Research

RSS
JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer

JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer

Combination therapy shows great promise as a new strategy against advanced lung cancer

Combination therapy shows great promise as a new strategy against advanced lung cancer

JAK inhibitor ruxolitinib enhances immunotherapy in Hodgkin lymphoma patients

JAK inhibitor ruxolitinib enhances immunotherapy in Hodgkin lymphoma patients

Unraveling nuanced roles of JAK inhibitors in inflammation

Unraveling nuanced roles of JAK inhibitors in inflammation

Two new practice parameters offer recommendations for treating anaphylaxis and atopic dermatitis

Two new practice parameters offer recommendations for treating anaphylaxis and atopic dermatitis

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

JAK inhibitors offer effective and convenient treatment option for arthritis patients

JAK inhibitors offer effective and convenient treatment option for arthritis patients

Lack of direct comparisons prevents assessment of upadacitinib's benefit in Crohn's disease

Lack of direct comparisons prevents assessment of upadacitinib's benefit in Crohn's disease

Study reveals immune dysregulation in Down syndrome and potential therapeutic strategy

Study reveals immune dysregulation in Down syndrome and potential therapeutic strategy

Patients with myelofibrosis show improvement in disease-related symptoms when treated with momelotinib

Patients with myelofibrosis show improvement in disease-related symptoms when treated with momelotinib

CHLA launches first clinical trial for Down syndrome regression disorder with $5.3 million NIH grant

CHLA launches first clinical trial for Down syndrome regression disorder with $5.3 million NIH grant

Study reviews mechanistic data on new methods of allergy prevention and treatment

Study reviews mechanistic data on new methods of allergy prevention and treatment

Does skin inflammation exacerbate COVID-19?

Does skin inflammation exacerbate COVID-19?

Antibody drugs are not recommended for patients with covid-19, say WHO experts

Antibody drugs are not recommended for patients with covid-19, say WHO experts

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

Oral pill taken once a day improves outcomes of patients with myelofibrosis

Oral pill taken once a day improves outcomes of patients with myelofibrosis

Cycling JAK inhibitors can be effective for treating people with difficult-to-treat rheumatoid arthritis

Cycling JAK inhibitors can be effective for treating people with difficult-to-treat rheumatoid arthritis

Study shows impaired SARS-CoV-2 mRNA vaccine antibody response in individuals with chronic conditions

Study shows impaired SARS-CoV-2 mRNA vaccine antibody response in individuals with chronic conditions

Autoimmune condition biomarkers promote SARS-CoV-2 viral entry, study finds

Autoimmune condition biomarkers promote SARS-CoV-2 viral entry, study finds

Novel super-activating macrophage receptor could explain hyper-inflammation in severe COVID-19

Novel super-activating macrophage receptor could explain hyper-inflammation in severe COVID-19

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.